Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)
- PMID: 37099213
- PMCID: PMC10219861
- DOI: 10.1007/s12325-023-02489-y
Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)
Abstract
This is a summary of the original article 'Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)'. Individuals with insomnia are best positioned to assess the impact of insomnia on their quality of life. Patient reported outcomes (PROs) are self-reported health measures created to allow people to record their experience of their disease. Chronic insomnia has a major impact on daytime functioning for patients, and on their quality of life. This summary of research provides an overview of a previously published article detailing the development and evaluation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), as a tool to allow people with insomnia to report their experience of the impact on their daytime functioning.
© 2023. The Author(s).
Conflict of interest statement
Stacie Hudgens and Louise Newton are employees of Clinical Outcomes Solutions. Clinical Outcomes Solutions was funded by Actelion and Idorsia to conduct the observational study, psychometrics validation, and exit interviews. Andrea Phillips-Beyer is the director of Innovus Consulting Ltd., which provided consulting services for Idorsia Pharmaceuticals Ltd., and received payment for the work outlined in the manuscript. Dalma Seboek Kinter is an employee and shareholder of Idorsia Pharmaceuticals Ltd. Heike Benes is an employee of Somni Bene Institut fűr Medizinische Forschung und Schlafmedizin Schwerin GmbH and the University of Robock Medical Center, Germany, which received financial support for conducting the interventional study.
Similar articles
-
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant.Pharmaceut Med. 2023 Jul;37(4):291-303. doi: 10.1007/s40290-023-00484-w. Epub 2023 Jun 7. Pharmaceut Med. 2023. PMID: 37286927 Free PMC article. Clinical Trial.
-
Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).Patient. 2021 Mar;14(2):249-268. doi: 10.1007/s40271-020-00474-z. Epub 2020 Nov 1. Patient. 2021. PMID: 33131027 Free PMC article.
-
Content Validity Assessment of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Among Adults with Insomnia and Nocturia.Patient. 2025 May;18(3):249-261. doi: 10.1007/s40271-025-00733-x. Epub 2025 Feb 27. Patient. 2025. PMID: 40014275 Free PMC article.
-
Issues in the diagnosis and treatment of insomnia.Psychopharmacology Suppl. 1984;1:11-43. doi: 10.1007/978-3-642-69659-6_2. Psychopharmacology Suppl. 1984. PMID: 6382252 Review.
-
Insomnia and Insomnia Symptoms in Persons With Heart Failure: An Integrative Review.J Cardiovasc Nurs. 2021 Jul-Aug 01;36(4):374-384. doi: 10.1097/JCN.0000000000000719. J Cardiovasc Nurs. 2021. PMID: 32649375 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous